Riskpilot← Back to searchSign inGet full accessMicrobiotech/se AB
ABActiveOrg 5565128658Svärdlångsvägen 32 2 TrWholesale of pharmaceutical and medical goods · NACE 4646Est. 19954 employees
Revenue 2025
SEK 3,2M
+2% vs 2024
EBITDA margin
-0.7%
-110% vs 2024
Equity ratio
71.7%
Financial strength
Net profit 2025
SEK -11K
-105% vs 2024
| Revenue | SEK 3,2M | +2% |
| EBITDA | SEK -24K | -110% |
| Net profit | SEK -11K | -105% |
| Total assets | SEK 2,3M | +0% |
| Equity | SEK 1,6M | -1% |
| Employees | 4 | — |
Legal name
Microbiotech/se AB
Org number
5565128658
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
13 maj 1995
Share capital
SEK 330 000
Employees
4 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget skall driva handel, produktion och marknadsföring av produkter såsom rostfria artiklar och laboratorieutrustning inom området för sjukhus, offentliga sektor och storkök samt bedriva forskning och utveckling inom ovanstående områden, äga och förvalta fast egendom och värdepapper, därmed förenlig verksamhet.
Address
Svärdlångsvägen 32 2 Tr
Email
mab@microbiotech.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 540 | 3 195 | 2 659 | 3 107 | 3 183 |
| Staff expenses | — | — | — | −1 287 | −1 507 |
| EBITDA | 580 | −62 | 23 | 236 | −24 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | 580 | −62 | 23 | 236 | −24 |
| Net financials | — | — | −1 | 11 | 13 |
| Profit before tax | 434 | 116 | 94 | 312 | −10 |
| Tax | −94 | −28 | −23 | −70 | −1 |
| Net profit | 340 | 88 | 71 | 242 | −11 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 468 | 2 535 | 2 242 | 2 288 | 2 284 |
| Equity | 1 248 | 1 337 | 1 408 | 1 650 | 1 639 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 533 | 691 | 399 | 269 | 276 |
| Total debt | 533 | 691 | 399 | 269 | 276 |
EBITDA margin
-0.7%
This company
15.8%
Market median
-104% vs market
20212025
Equity ratio
71.7%
This company
38.2%
Market median
+88% vs market
20212025
Return on equity
-0.7%
This company
18.4%
Market median
-104% vs market
20212025
Net profit margin
-0.3%
This company
8.1%
Market median
-104% vs market
20212025
Asset turnover
1.39×
This company
1.12×
Market median
+24% vs market
20212025
Debt / equity
0.39×
This company
0.62×
Market median
+37% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CA | Audit | 2023 |
| Former (1) | ||
HO Audit | Audit | 2022 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Chairman | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Microbiotech/se AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Caroline Anna Ljungberg | Audit | 0 companies |
| Hans-Olof Olsson | Audit | 0 companies |
| Bert Roland Diseus | Board of Directors | 0 companies |
| Lars Håkan Anders Björk | Board of Directors | 0 companies |
| Peer Model | Chairman | 0 companies |